Sign in

    Selena Zhang

    Vice President and Equity Research Analyst at Morgan Stanley

    Selena Zhang is a Vice President and Equity Research Analyst at Morgan Stanley, specializing in the technology and internet sector with a focus on Chinese tech companies. She covers leading firms such as Alibaba, Tencent, Meituan, and JD.com, and is recognized for her in-depth market insights and accurate investment calls, boasting a success rate above 68% and strong average returns as ranked on platforms like TipRanks. Zhang began her career at J.P. Morgan as an analyst before joining Morgan Stanley in 2019, where she quickly rose to her current VP role and has been noted for her sector expertise and impactful research publications. She holds FINRA Series 7 and 63 licenses and is known for her timely market commentary and recognition among industry peers for her research excellence.

    Selena Zhang's questions to Mirum Pharmaceuticals (MIRM) leadership

    Selena Zhang's questions to Mirum Pharmaceuticals (MIRM) leadership • Q1 2025

    Question

    On behalf of Mike Ulz, Selena Zhang asked for an update on LIVMARLI's market access versus competitors and how step-through policies are evolving for both Alagille syndrome and PFIC indications.

    Answer

    President and Chief Operating Officer Peter Radovich stated that U.S. access for LIVMARLI is very strong and not a barrier. He acknowledged that while some policies give LIVMARLI a preferential step-through position, the primary drivers of its success are its strong clinical value proposition and the comprehensive support Mirum provides.

    Ask Fintool Equity Research AI